THEORETICAL AND PRACTICAL IMPLICATIONS OF A HEDONIC PRICING MODEL: EMPIRICAL OBSERVATIONS FROM WHOLESALE AUTOMOBILE AUCTIONS

Wholesale auto auctions are convenient structures for economists as they attempt to observe the marginal effects of quality changes on the market-clearing price. However, what may be categorized as a quality change might rather be a market signal of an environment with adverse selection. This dissertation analyzes the effects of seller type and tests their sensitivity to econometric model specification. General hedonic attributes and their various applications are reviewed. This dissertation explores the basic auto auction environment and dispels inaccurate notions about the auction structure. Following Bartik\u27s (1987) analysis, multi-market data are used to produce hedonic estimates for seller, mileage and other attributes. A section is devoted to the peculiarities of the auction environment; namely, the winner\u27s curse, adverse selection, and variations in auction structure. A three-part literature review covers adverse selection, the various technicalities of auction structure, and the econometric issues regarding hedonic regressions. A section presents the data and the econometric models with their results. Concluding remarks discuss areas for further research

Simple, Compact, Safe Impact Tester

An apparatus has been designed and built for testing the effects, on moderate-sized objects, of cushioned decelerations having magnitudes ranging up to several hundred g [where g = normal Earth gravitational acceleration (approximately 9.8 m/s(exp 2))]

AdCraft: An Advanced Reinforcement Learning Benchmark Environment for Search Engine Marketing Optimization

We introduce AdCraft, a novel benchmark environment for the Reinforcement Learning (RL) community distinguished by its stochastic and non-stationary properties. The environment simulates bidding and budgeting dynamics within Search Engine Marketing (SEM), a digital marketing technique utilizing paid advertising to enhance the visibility of websites on search engine results pages (SERPs). The performance of SEM advertisement campaigns depends on several factors, including keyword selection, ad design, bid management, budget adjustments, and performance monitoring. Deep RL recently emerged as a potential strategy to optimize campaign profitability within the complex and dynamic landscape of SEM but it requires substantial data, which may be costly or infeasible to acquire in practice. Our customizable environment enables practitioners to assess and enhance the robustness of RL algorithms pertinent to SEM bid and budget management without such costs. Through a series of experiments within the environment, we demonstrate the challenges imposed by sparsity and non-stationarity on agent convergence and performance. We hope these challenges further encourage discourse and development around effective strategies for managing real-world uncertainties

Combining stereotactic body radiation therapy with immunotherapy: Current data and future directions

Stereotactic body radiation therapy (SBRT) offers excellent local control of early-stage non-small cell lung cancer (NSCLC), but there currently is a need for tolerable systemic therapy to address regional and distant disease progression. One potential option is immunotherapy, which in metastatic NSCLC has shown promise for sustained disease control in a subset of patients. There is also growing evidence for a clinical synergy between radiation and immunotherapy, with several ongoing trials studying the abscopal effect. This review summarizes the current data in the fast-changing field of immuno-radiation therapy, highlighting updates from recent clinical trials

Emerging Technologies for Gut Microbiome Research

Understanding the importance of the gut microbiome on modulation of host health has become a subject of great interest for researchers across disciplines. As an intrinsically multidisciplinary field, microbiome research has been able to reap the benefits of technological advancements in systems and synthetic biology, biomaterials engineering, and traditional microbiology. Gut microbiome research has been revolutionized by high-throughput sequencing technology, permitting compositional and functional analyses that were previously an unrealistic undertaking. Emerging technologies including engineered organoids derived from human stem cells, high-throughput culturing, and microfluidics assays allowing for the introduction of novel approaches will improve the efficiency and quality of microbiome research. Here, we will discuss emerging technologies and their potential impact on gut microbiome studies

Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: A review of the National Cancer Database

For elderly patients with locally advanced esophageal cancer, therapeutic approaches and outcomes in a modern cohort are not well characterized. Patients ≥70 years old with clinical stage II and III esophageal cancer diagnosed between 1998 and 2012 were identified from the National Cancer Database and stratified based on treatment type. Variables associated with treatment utilization were evaluated using logistic regression and survival evaluated using Cox proportional hazards analysis. Propensity matching (1:1) was performed to help account for selection bias. A total of 21,593 patients were identified. Median and maximum ages were 77 and 90, respectively. Treatment included palliative therapy (24.3%), chemoradiation (37.1%), trimodality therapy (10.0%), esophagectomy alone (5.6%), or no therapy (12.9%). Age ≥80 (OR 0.73), female gender (OR 0.81), Charlson-Deyo comorbidity score ≥2 (OR 0.82), and high-volume centers (OR 0.83) were associated with a decreased likelihood of palliative therapy versus no treatment. Age ≥80 (OR 0.79) and Clinical Stage III (OR 0.33) were associated with a decreased likelihood, while adenocarcinoma histology (OR 1.33) and nonacademic cancer centers (OR 3.9), an increased likelihood of esophagectomy alone compared to definitive chemoradiation. Age ≥80 (OR 0.15), female gender (OR 0.80), and non-Caucasian race (OR 0.63) were associated with a decreased likelihood, while adenocarcinoma histology (OR 2.10) and high-volume centers (OR 2.34), an increased likelihood of trimodality therapy compared to definitive chemoradiation. Each treatment type demonstrated improved survival compared to no therapy: palliative treatment (HR 0.49) to trimodality therapy (HR 0.25) with significance between all groups. Any therapy, including palliative care, was associated with improved survival; however, subsets of elderly patients with locally advanced esophageal cancer are less likely to receive aggressive therapy. Care should be taken to not unnecessarily deprive these individuals of treatment that may improve survival

Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)

Background: There is increasing interest in treating oligometastatic non-small cell lung cancer (NSCLC) patients with stereotactic radiation. We aimed to address whether patients definitively treated with synchronous thoracic stereotactic body radiation therapy (SBRT) and brain stereotactic radiosurgery (SRS) had favorable outcomes with local therapy. Materials and methods: We reviewed a database of patients receiving lung SBRT as well as a database for brain metastasis patients treated with SRS between June 2004 and January 2016. We selected for cT1-2aN0M1 NSCLC patients with brain metastases and calculated their overall survival (OS), freedom from progression (FFP), and local control (LC) rates. Results: Six patients had oligometastatic NSCLC with 1-3 synchronous brain metastases treated with lung SBRT and brain SRS. No patients received immunotherapy and two-thirds did not receive systemic therapy. Median follow-up was 9 months for the entire cohort (range, 2-95 months) and 95 months for the surviving patient. Median OS was 12.4 months (95% confidence interval [CI], 7-18 months). At 1 year, patients had 67% OS (95% CI, 29-100%), 17% FFP (95% CI, 0-46%), and 100% LC. Their brain disease had 80% 1-year LC (95% CI, 45-100%) and 53% 1-year FFP (95% CI, 5-100%). Two patients had no distant progression, two had brain progression, one had adrenal gland progression, and one had bone and liver progression. Conclusion: In patients presenting with oligometastatic lung cancer limited to the brain, treatment with both lung SBRT and brain SRS achieves good LC of all sites with encouraging OS